logo
Plus   Neg
Share
Email

MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

MorphoSys AG (MOR,MPSYY.PK) and Incyte Corp. (INCY) have agreed on a collaboration and license agreement to further develop and commercialize MorphoSys' anti-CD19 antibody tafasitamab (MOR208) globally. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S. Incyte has exclusive commercialization rights outside of the U.S.

Tafasitamab is an Fc-engineered antibody currently in clinical development for the treatment of B cell malignancies. MorphoSys recently submitted a Biologics License Application for tafasitamab, in combination with lenalidomide, to the FDA for the treatment of relapsed/refractory diffuse large B cell lymphoma.

MorphoSys will receive an upfront payment of $750 million. Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys. Under the terms of the agreement, MorphoSys will be also eligible to receive milestone payments amounting to up to $1.1 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT